Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Gynecology

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 50 articles: HTML format

Single Articles

October 2025
1. DURAN GE, Wang YC, Moisan F, Francisco EB, et al
   Editorial Expression of Concern: Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.
   Br J Cancer. 2025 Oct 6. doi: 10.1038/s41416-025-03231.
   PubMed    
   
   
   
2. BAENA A, Picconi MA, Mendoza L, Ferrera A, et al
   Short-term repeat HPV testing for triaging HPV-positive women in cervical cancer screening.
   Br J Cancer. 2025 Oct 3. doi: 10.1038/s41416-025-03193.
   PubMed     Abstract available
   
   
   
3. CHANG YH, Bresnahan ST, Taylor Head S, Harrison TA, et al
   Isoform-level analyses of 6 cancers uncover extensive genetic risk mechanisms undetected at the gene-level.
   Br J Cancer. 2025;133:874-885.
   PubMed     Abstract available
   
   
   September 2025
4. WU R, Arendse KD, Hamdani T, Walter FM, et al
   Cost-effectiveness of CA125- and age-informed risk-based triage for ovarian cancer detection in primary care.
   Br J Cancer. 2025 Sep 17. doi: 10.1038/s41416-025-03166.
   PubMed     Abstract available
   
   
   
5. ARENDSE KD, Walter FM, Abel G, Rous B, et al
   CA125 and age-based models for ovarian cancer detection in primary care: a population-based external validation study.
   Br J Cancer. 2025 Sep 17. doi: 10.1038/s41416-025-03165.
   PubMed     Abstract available
   
   
   
6. GORI S, Venturelli F, Carozzi F, Giorgi Rossi P, et al
   Italian guidelines for cervical cancer screening. Multisocietal recommendations on the use of biomarkers in HPV screening with risk-based approach and GRADE methodology.
   Br J Cancer. 2025 Sep 11. doi: 10.1038/s41416-025-03161.
   PubMed     Abstract available
   
   
   
7. MATHEWS CS, Sargent A, Cuschieri K, Rebolj M, et al
   HPValidate-human papillomavirus testing with DNA and mRNA assays on self-collected samples in cervical screening: comparison of test characteristics on three self-sampling devices.
   Br J Cancer. 2025;133:665-673.
   PubMed     Abstract available
   
   
   August 2025
8. MULUGETA A, Stacey D, Lumsden AL, Madakkatel I, et al
   Protein markers of ovarian cancer and its subtypes: insights from proteome-wide Mendelian randomisation analysis.
   Br J Cancer. 2025 Aug 28. doi: 10.1038/s41416-025-03143.
   PubMed     Abstract available
   
   
   
9. STOER NC, Vangen S, Singh D, Fortner RT, et al
   Correction: Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway.
   Br J Cancer. 2025 Aug 20. doi: 10.1038/s41416-025-03038.
   PubMed    
   
   
   July 2025
10. SOOI K, Tan TZ, Kim JW, Lee JY, et al
    A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients.
    Br J Cancer. 2025 Jul 22. doi: 10.1038/s41416-025-03090.
    PubMed     Abstract available
    
    
    
11. YIN C, Adenekan TA, Deng C, Hansen J, et al
    Application of an obstetric comorbidity index to predict childhood cancer risk: a population based case-control study in Denmark.
    Br J Cancer. 2025 Jul 21. doi: 10.1038/s41416-025-03120.
    PubMed     Abstract available
    
    
    
12. FICORELLA L, Yang X, Mavaddat N, Carver T, et al
    Adapting the BOADICEA breast and ovarian cancer risk models for the ethnically diverse UK population.
    Br J Cancer. 2025 Jul 17. doi: 10.1038/s41416-025-03117.
    PubMed     Abstract available
    
    
    June 2025
13. STANGE C, Dreyer TF, Riedel M, Elsen F, et al
    PARP inhibitor-induced anti-tumour chemokine response is suppressed by dipeptidyl peptidase 4 (DPP4) in ovarian cancer.
    Br J Cancer. 2025 Jun 27. doi: 10.1038/s41416-025-03076.
    PubMed     Abstract available
    
    
    
14. LIU Y, Chen Z, Duan Y, Shao Z, et al
    Spliceosomal GTPase EFTUD2 mediates DDX41 intron retention to promote the malignant progression of ovarian cancer.
    Br J Cancer. 2025 Jun 24. doi: 10.1038/s41416-025-03079.
    PubMed     Abstract available
    
    
    
15. NARAYANAN B, Buddenkotte T, Smith H, Shah M, et al
    Growth kinetics of high-grade serous ovarian cancer: implications for early detection.
    Br J Cancer. 2025 Jun 12. doi: 10.1038/s41416-025-03082.
    PubMed     Abstract available
    
    
    May 2025
16. SCHIEMER R, Grant J, Shafiee MN, Phang S, et al
    Infrared and Raman spectroscopy of blood plasma for rapid endometrial cancer detection.
    Br J Cancer. 2025 May 18. doi: 10.1038/s41416-025-03050.
    PubMed     Abstract available
    
    
    
17. TYRAKIS PA, Kampjut D, Steele GF, Lindstrom HJG, et al
    Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kalpha potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models.
    Br J Cancer. 2025 May 13. doi: 10.1038/s41416-025-03035.
    PubMed     Abstract available
    
    
    April 2025
18. TREWIN-NYBRATEN CB, Leithe S, Paulsen T, Langseth H, et al
    Ovarian cancer survival by residual disease following cytoreductive surgery: a nationwide study in Norway.
    Br J Cancer. 2025 Apr 26. doi: 10.1038/s41416-025-03018.
    PubMed     Abstract available
    
    
    
19. LAGA T, Van Rompuy AS, Busschaert P, Marquina G, et al
    Single-cell profiling in ovarian germ cell and sex cord-stromal tumours.
    Br J Cancer. 2025 Apr 23. doi: 10.1038/s41416-025-03012.
    PubMed     Abstract available
    
    
    
20. SU H, Jin X, Kong L, You Y, et al
    The triage role of cytological DNA methylation in women with non-16/18, specifically genotyping high-risk HPV infection.
    Br J Cancer. 2025 Apr 10. doi: 10.1038/s41416-025-03005.
    PubMed     Abstract available
    
    
    March 2025
21. PIGNATA S, Oza A, Hall G, Pardo B, et al
    Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status.
    Br J Cancer. 2025 Mar 17. doi: 10.1038/s41416-025-02966.
    PubMed     Abstract available
    
    
    
22. YE X, Zheng J, Hu D, Liu L, et al
    Identification of increased dedifferentiation along the Prom1+ cancer cells in Mullerian adenosarcoma with sarcomatous overgrowth.
    Br J Cancer. 2025;132:438-449.
    PubMed     Abstract available
    
    
    December 2024
23. MERRITT MA, Abe SK, Islam MR, Rahman MS, et al
    Reproductive factors and risk of epithelial ovarian cancer: results from the Asia Cohort Consortium.
    Br J Cancer. 2024 Dec 20. doi: 10.1038/s41416-024-02924.
    PubMed     Abstract available
    
    
    
24. LIU C, Reger M, Fan H, Wang J, et al
    Dietary intake of isoflavones and coumestrol and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2024 Dec 16. doi: 10.1038/s41416-024-02929.
    PubMed     Abstract available
    
    
    
25. XU Q, Kowalski J
    Non-B DNA-informed mutation burden as a marker of treatment response and outcome in cancer.
    Br J Cancer. 2024;131:1825-1832.
    PubMed     Abstract available
    
    
    November 2024
26. MORGAN RD, Wang X, Barnes BM, Spurgeon L, et al
    Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer.
    Br J Cancer. 2024 Nov 16. doi: 10.1038/s41416-024-02874.
    PubMed     Abstract available
    
    
    
27. TAN R, Wen M, Yang W, Zhan D, et al
    Integrated proteomics and scRNA-seq analyses of ovarian cancer reveal molecular subtype-associated cell landscapes and immunotherapy targets.
    Br J Cancer. 2024 Nov 15. doi: 10.1038/s41416-024-02894.
    PubMed     Abstract available
    
    
    
28. ZAHID MU, Waguespack M, Harman RC, Kercher EM, et al
    Fractionated photoimmunotherapy stimulates an anti-tumour immune response: an integrated mathematical and in vitro study.
    Br J Cancer. 2024;131:1378-1386.
    PubMed     Abstract available
    
    
    October 2024
29. HIRAHARA Y, Shimizu K, Yamasaki S, Iyoda T, et al
    Crucial immunological roles of the invasion front in innate and adaptive immunity in cervical cancer.
    Br J Cancer. 2024 Oct 29. doi: 10.1038/s41416-024-02877.
    PubMed     Abstract available
    
    
    
30. SUN Y, Yin Z, Li S, Wu L, et al
    Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer.
    Br J Cancer. 2024 Oct 5. doi: 10.1038/s41416-024-02863.
    PubMed     Abstract available
    
    
    September 2024
31. YANG X, Wu Y, Ficorella L, Wilcox N, et al
    Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank.
    Br J Cancer. 2024 Sep 18. doi: 10.1038/s41416-024-02851.
    PubMed     Abstract available
    
    
    
32. KRISTELEIT R, Leary A, Oaknin A, Redondo A, et al
    PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers.
    Br J Cancer. 2024;131:820-831.
    PubMed     Abstract available
    
    
    
33. SMITH HL, Willmore E, Prendergast L, Curtin NJ, et al
    ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors.
    Br J Cancer. 2024;131:905-917.
    PubMed     Abstract available
    
    
    
34. SUVAAL I, Hummel SB, Mens JM, Tuijnman-Raasveld CC, et al
    Efficacy of a nurse-led sexual rehabilitation intervention for women with gynaecological cancers receiving radiotherapy: results of a randomised trial.
    Br J Cancer. 2024;131:808-819.
    PubMed     Abstract available
    
    
    August 2024
35. TAKAMATSU S, Hillman RT, Yoshihara K, Baba T, et al
    Molecular classification of ovarian high-grade serous/endometrioid carcinomas through multi-omics analysis: JGOG3025-TR2 study.
    Br J Cancer. 2024 Aug 30. doi: 10.1038/s41416-024-02837.
    PubMed     Abstract available
    
    
    
36. ZHUO L, Meng F, Sun K, Zhou M, et al
    Integrated immuno-transcriptomic analysis of ovarian cancer identifies a four-chemokine-dominated subtype with antitumor immune-active phenotype and favorable prognosis.
    Br J Cancer. 2024 Aug 2. doi: 10.1038/s41416-024-02803.
    PubMed     Abstract available
    
    
    July 2024
37. NAGLE CM, Ibiebele TI, Bandera EV, Cramer D, et al
    Pre-diagnosis tea and coffee consumption and survival after a diagnosis of ovarian cancer: results from the Ovarian Cancer Association Consortium.
    Br J Cancer. 2024 Jul 18. doi: 10.1038/s41416-024-02792.
    PubMed     Abstract available
    
    
    June 2024
38. ARONSON SL, Walker C, Thijssen B, van de Vijver KK, et al
    Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1).
    Br J Cancer. 2024 Jun 12. doi: 10.1038/s41416-024-02731.
    PubMed     Abstract available
    
    
    
39. QIU L, Li R, Wang Y, Lu Z, et al
    PTEN inhibition enhances sensitivity of ovarian cancer cells to the poly (ADP-ribose) polymerase inhibitor by suppressing the MRE11-RAD50-NBN complex.
    Br J Cancer. 2024 Jun 12. doi: 10.1038/s41416-024-02749.
    PubMed     Abstract available
    
    
    May 2024
40. STOER NC, Vangen S, Singh D, Fortner RT, et al
    Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway.
    Br J Cancer. 2024 May 13. doi: 10.1038/s41416-024-02590.
    PubMed     Abstract available
    
    
    
41. KENKHUIS MF, Stelten S, Hartman YA, Brouwer CG, et al
    Effects of a combined exercise and dietary intervention on body composition, physical functioning and fatigue in patients with ovarian cancer: results of the PADOVA trial.
    Br J Cancer. 2024 May 8. doi: 10.1038/s41416-024-02694.
    PubMed     Abstract available
    
    
    
42. HERMAN L, Amo A, Legois B, Di Carlo C, et al
    A cellular model provides insights into the pathogenicity of the oncogenic FOXL2 somatic variant p.Cys134Trp.
    Br J Cancer. 2024;130:1453-1462.
    PubMed     Abstract available
    
    
    
43. REBOLJ M, Brentnall AR, Cuschieri K
    Predictable changes in the accuracy of human papillomavirus tests after vaccination: review with implications for performance monitoring in cervical screening.
    Br J Cancer. 2024;130:1733-1743.
    PubMed     Abstract available
    
    
    
44. NG CW, Tsang YTM, Gershenson DM, Wong KK, et al
    The prognostic value of MEK pathway-associated estrogen receptor signaling activity for female cancers.
    Br J Cancer. 2024;130:1875-1884.
    PubMed     Abstract available
    
    
    April 2024
45. DHAR C, Ramachandran P, Xu G, Pickering C, et al
    Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profiling.
    Br J Cancer. 2024 Apr 24. doi: 10.1038/s41416-024-02644.
    PubMed     Abstract available
    
    
    
46. PORTNOY A, Pedersen K, Kim JJ, Burger EA, et al
    Vaccination and screening strategies to accelerate cervical cancer elimination in Norway: a model-based analysis.
    Br J Cancer. 2024 Apr 20. doi: 10.1038/s41416-024-02682.
    PubMed     Abstract available
    
    
    
47. KMENT J, Newsted D, Young S, Vermeulen MC, et al
    Blockade of TGF-beta and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses.
    Br J Cancer. 2024 Apr 15. doi: 10.1038/s41416-024-02677.
    PubMed     Abstract available
    
    
    
48. TIAN Y, Lin Y, Qu C, Arndt V, et al
    Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk.
    Br J Cancer. 2024 Apr 1. doi: 10.1038/s41416-024-02638.
    PubMed     Abstract available
    
    
    March 2024
49. ROQUE DM, Siegel ER, Buza N, Bellone S, et al
    Correction: Randomised phase II trial of weekly ixabepilone +/- biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
    Br J Cancer. 2024 Mar 4. doi: 10.1038/s41416-024-02628.
    PubMed    
    
    
    
50. MATOBA Y, Zarrella DT, Pooladanda V, Azimi Mohammadabadi M, et al
    Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma.
    Br J Cancer. 2024 Mar 4. doi: 10.1038/s41416-024-02621.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.